Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Elicio Therapeutics Inc.

Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Secures $10 Million in Financing
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Announces Proposed Public Offering
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.